Table 4 Meta-analysis for the association of NFKB- and inflammosome-related polymorphisms and RA risk in ACPA+ patients.

From: NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium

Gene

SNP ID

Chr.

Effect allele

Discovery population ACPA+ RA vs. controls (n = 1971)

Replication DANBIO Registry ACPA+ RA vs. controls (n = 1741)

Meta-analysis ACPA+ RA vs. controls (n = 3712)

OR (95% CI)∂

P

OR (95% CI)∂

P

OR (95% CI)∂

P

I2

GBP6

rs928655

1

A

0.88 (0.74–1.04)

0.14

1.24 (0.97–1.58)

0.079

1.03 (0.74–1.44)

0.85

0.024

IKBKB

rs11986055

8

A

1.15 (0.83–1.62)

0.40

—

—

—

—

—

IRF4

rs1050975

6

A

1.51 (1.14–1.99)§

0.003

0.93 (0.65–1.32)§

0.68

1.12 (0.74–1.93)§

0.45

0.035

IRF4

rs12203592

6

T

0.99 (0.78–1.24)

0.92

—

—

—

—

—

IRF4

rs1877175

6

T

0.86 (0.75–1.01)

0.065

1.06 (0.84–1.33)

0.61

0.93 (0.77–1.15)

0.52

0.13

IRF4

rs7768807

6

T

0.93 (0.78–1.09)

0.36

—

—

—

—

—

KLRC1

rs7301582

12

T

1.15 (0.97–1.37)

0.096

0.85 (0.67–1.08)

0.19

1.00 (0.74–1.34)

1.00

0.044

KLRK1 | KLRC4

rs1049174

12

C

1.06 (0.90–1.25)

0.45

0.95 (0.76–1.19)

0.66

—

—

—

KLRK1 | KLRC4

rs1154831

12

A

1.05 (0.88–1.26)

0.59

—

—

—

—

—

KLRK1 | KLRC4

rs2255336

12

A

1.04 (0.87–1.25)

0.68

—

—

—

—

—

LOC105376246

rs2722824

9

A

0.93 (0.79–1.10)

0.41

—

—

—

—

—

NFKB1

rs4648110

4

A

1.16 (0.97–1.39)

0.11

—

—

—

—

—

NFKB2

rs11574851

10

T

1.39 (1.06–1.83)

0.017

1.72 (1.14–2.59)

0.009

1.48 (1.18–1.86)

0.0006

0.40

NFKB2

rs12769316

10

T

1.70 (0.95–3.06)§

0.077

1.91 (0.93–3.92)§

0.080

1.78 (1.13–2.80)§

0.013

0.81

NFKB2 | PSD

rs1056890

10

T

0.95 (0.81–1.12)

0.56

—

—

—

—

—

NFKBIB

rs3136645

19

C

1.15 (0.95–1.38)

0.14

—

—

—

—

—

NLRP3

rs4612666

1

T

1.29 (1.04–1.60)†

0.020

1.06 (0.81–1.39)†

0.68

1.19 (0.99–1.44)†

0.072

0.27

REL

rs13031237

2

T

1.15 (0.85–1.53)§

0.36

1.15 (0.78–1.70)§

0.47

1.15 (0.91–1.45)§

0.24

1.00

REL

rs842647

2

A

1.10 (0.93–1.31)

0.27

—

—

—

—

—

REL

rs13017599

2

A

1.04 (0.89–1.21)

0.64

1.02 (0.83–1.25)

0.86

1.03 (0.91–1.17)

0.61

0.88

RELA

rs11820062

11

T

0.91 (0.78–1.05)

0.20

—

—

—

—

—

RELA

rs2306365

11

A

1.02 (0.81–1.28)

0.86

—

—

—

—

—

RELA

rs7119750

11

T

1.04 (0.82–1.30)

0.76

—

—

—

—

—

TLR10

rs11096957

4

A

1.13 (0.98–1.32)

0.10

0.75 (0.60–0.93)

0.010

0.93 (0.62–1.39)

0.72

0.002

TLR4

rs4986791

9

T

1.15 (0.83–1.60)

0.40

—

—

—

—

—

TLR5

rs5744174

1

C

1.03 (0.88–1.20)

0.75

—

—

—

—

—

TLR9 | | TWF2

rs187084

3

T

0.93 (0.80–1.09)

0.39

—

—

—

—

—

TRAF1 | | C5

rs3761847

9

A

1.00 (0.86–1.17)

0.99

—

—

—

—

—

  1. Abbreviations: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.
  2. A random effect model was assumed for the meta-analysis of both cohorts.
  3. ∂Estimates calculated according to an additive model of inheritance and adjusted for age and sex.
  4. †Estimates calculated according to a dominant model of inheritance and adjusted for age and sex.
  5. §Estimates calculated according to a recessive model of inheritance and adjusted for age and sex.
  6. P < 0.05 in boldface.
Back to article page